Hypoxia-inducible factor 2α is a negative regulator of osteoblastogenesis and bone mass accrual

Abstract

Osteoblasts, which are the bone-forming cells, operate in a hypoxic environment. The transcription factors hypoxia-inducible factor-1α (HIF1) and HIF2 are key mediators of the cellular response to hypoxia. Both are expressed in osteoblasts. HIF1 is known to be a positive regulator of bone formation. Conversely, the role of HIF2 in the control osteoblast biology is still poorly understood. In this study, we used mouse genetics to demonstrate that HIF2 is an inhibitor of osteoblastogenesis and bone mass accrual. Moreover, we provided evidence that HIF2 impairs osteoblast differentiation at least in part, by upregulating the transcription factor Sox9. Our findings constitute a paradigm shift, as activation of the hypoxia-signaling pathway has traditionally been associated with increased bone formation through HIF1. Inhibiting HIF2 could thus represent a therapeutic approach for the treatment of the low bone mass observed in chronic diseases, osteoporosis, or aging.

Bone formation: Signaling in the opposite direction

The regulation of gene expression by hypoxia-inducible factor 2 (HIF2) prevents bone formation by inhibiting the differentiation of mesenchymal cells into osteoblasts. Ernestina Schipani at the University of Michigan, USA, and colleagues found that the bone mass of mice expressing a stabilized version of HIF2 was reduced compared with controls. This effect was associated with HIF2−mediated activation of the transcription factor SOX9, which disrupts osteoblastogenesis and stimulates the formation of cartilage cells. Interestingly, HIF1, which shares 48% overall amino acid identity with HIF2, is an established positive regulator of bone formation. These findings suggest that the opposing actions of HIF1 and HIF2 could be key for regulating bone growth. Furthermore, they raise the interesting possibility of using HIF2 inhibitors for the treatment of diseases characterized by low bone mass such as osteoporosis.

References

[1] Karsenty G, Kronenberg HM, Settembre C. Genetic control of bone formation. Annu Rev. Cell Dev. Biol., 2009, 25:629-648

[2] Roberts SJ, van Gastel N, Carmeliet G, Luyten FP. Uncovering the periosteum for skeletal regeneration: the stem cell that lies beneath. Bone, 2015, 70:10-18

[3] Schipani, E. & Kronenberg, H. M. in StemBook (2008).

[4] Ducy P, Zhang R, Geoffroy V, Ridall A, Karsenty G. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell, 1997, 89:747-754

[5] Nakashima K et al. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell, 2002, 108:17-29

[6] Bonewald LF. The amazing osteocyte. J. Bone Miner. Res., 2011, 26:229-238

[7] Martin TJ, Sims NA. RANKL/OPG; Critical role in bone physiology. Rev. Endocr. Metab. Disord., 2015, 16:131-139

[8] Wu C et al. Oxygen-sensing PHDs regulate bone homeostasis through the modulation of osteoprotegerin. Genes & Dev., 2015, 29:817-831

[9] Semenza GL. Hypoxia-inducible factors in physiology and medicine. Cell, 2012, 148:399-408

[10] Keith B, Johnson RS, Simon MC. HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression. Nat. Rev. Cancer, 2011, 12:9-22

[11] Shomento SH et al. Hypoxia-inducible factors 1alpha and 2alpha exert both distinct and overlapping functions in long bone development. J. Cell Biochem., 2010, 109:196-204

[12] Rankin EB et al. The HIF signaling pathway in osteoblasts directly modulates erythropoiesis through the production of EPO. Cell, 2012, 149:63-74

[13] Regan JN et al. Up-regulation of glycolytic metabolism is required for HIF1alpha-driven bone formation. Proc. Natl. Acad. Sci. USA, 2014, 111:8673-8678

[14] Kim WY et al. Failure to prolyl hydroxylate hypoxia-inducible factor alpha phenocopies VHL inactivation in vivo. EMBO J., 2006, 25:4650-4662

[15] Shimada M, Greer PA, McMahon AP, Bouxsein ML, Schipani E. In vivo targeted deletion of calpain small subunit, Capn4, in cells of the osteoblast lineage impairs cell proliferation, differentiation, and bone formation. J. Biol. Chem., 2008, 283:21002-21010

[16] Gregory CA, Gunn WG, Peister A, Prockop DJ. An Alizarin red-based assay of mineralization by adherent cells in culture: comparison with cetylpyridinium chloride extraction. Anal. Biochem, 2004, 329:77-84

[17] Sinha P et al. Loss of gsalpha in the postnatal skeleton leads to low bone mass and a blunted response to anabolic parathyroid hormone therapy. J. Biol. Chem., 2016, 291:1631-1642

[18] Aro E et al. Hypoxia-inducible factor-1 (HIF-1) but not HIF-2 is essential for hypoxic induction of collagen prolyl 4-hydroxylases in primary newborn mouse epiphyseal growth plate chondrocytes. J. Biol. Chem., 2012, 287:37134-37144

[19] Calvi L et al. Activation of the PTH/PTHrP receptor in osteoblastic cells has differential effects on cortical and trabecular bone. J. Clin. Invest, 2001, 107:277-286

[20] Chiusaroli R et al. Collagenase cleavage of type I collagen is essential for both basal and parathyroid hormone (PTH)/PTH-related peptide receptor-induced osteoclast activation and has differential effects on discrete bone compartments. Endocrinology, 2003, 144:4106-4116

[21] Provot S, Schipani E. Molecular mechanisms of endochondral bone development. Biochem Biophys. Res Commun., 2005, 328:658-665

[22] Logan M et al. Expression of Cre recombinase in the developing mouse limb bud driven by a Prx1 enhancer. Genesis, 2002, 33:77-80

[23] Mangiavini L et al. Fibrosis and hypoxia-inducible factor-1alpha-dependent tumors of the soft tissue on loss of Von Hippel-Lindau in mesenchymal progenitors. Am. J. Pathol., 2015, 185:3090-3101

[24] Araldi E, Khatri R, Giaccia AJ, Simon MC, Schipani E. Lack of HIF-2alpha in limb bud mesenchyme causes a modest and transient delay of endochondral bone development. Nat. Med, 2011, 17:25-26 author reply 27-29

[25] Gruber M et al. Acute postnatal ablation of Hif-2alpha results in anemia. Proc. Natl. Acad. Sci. USA, 2007, 104:2301-2306

[26] Rankin EB et al. Hypoxia-inducible factor-2 regulates vascular tumorigenesis in mice. Oncogene, 2008, 27:5354-5358

[27] Arsham AM, Howell JJ, Simon MC. A novel hypoxia-inducible factor-independent hypoxic response regulating mammalian target of rapamycin and its targets. J. Biol. Chem., 2003, 278:29655-29660

[28] Brandao-Burch A, Utting JC, Orriss IR, Arnett TR. Acidosis inhibits bone formation by osteoblasts in vitro by preventing mineralization. Calcif. Tissue Int, 2005, 77:167-174

[29] Robins JC et al. Hypoxia induces chondrocyte-specific gene expression in mesenchymal cells in association with transcriptional activation of Sox9. Bone, 2005, 37:313-322

[30] Amarilio R et al. Hif1alpha regulation of Sox9 is necessary to maintain differentiation of hypoxic prechondrogenic cells during early chondrogenesis. Development, 2007, 134:3917-3928

[31] Dy P et al. Sox9 directs hypertrophic maturation and blocks osteoblast differentiation of growth plate chondrocytes. Dev. Cell, 2012, 22:597-609

[32] Zhou G et al. Dominance of SOX9 function over RUNX2 during skeletogenesis. Proc. Natl. Acad. Sci. USA, 2006, 103:19004-19009

[33] Liao J et al. Sox9 potentiates BMP2-induced chondrogenic differentiation and inhibits BMP2-induced osteogenic differentiation. PloS One, 2014, 9:e89025

[34] Lafont JE, Talma S, Hopfgarten C, Murphy CL. Hypoxia promotes the differentiated human articular chondrocyte phenotype through SOX9-dependent and -independent pathways. J. Biol. Chem., 2008, 283:4778-4786

[35] Schipani E, Wu C, Rankin EB, Giaccia AJ. Regulation of bone marrow angiogenesis by osteoblasts during bone development and homeostasis. Front. Endocrinol., 2013, 4:85

[36] Kusumbe AP, Ramasamy SK, Adams RH. Coupling of angiogenesis and osteogenesis by a specific vessel subtype in bone. Nature, 2014, 507:323-328

[37] Cho H et al. On-target efficacy of a HIF-2alpha antagonist in preclinical kidney cancer models. Nature, 2016, 539:107-111

[38] Kist R, Schrewe H, Balling R, Scherer G. Conditional inactivation of Sox9: a mouse model for campomelic dysplasia. Genesis, 2002, 32:121-123

[39] Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 2001, 25:402-408

[40] Irizarry RA et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics, 2003, 4:249-264

[41] Mangiavini L, Merceron C, Schipani E. Analysis of mouse growth plate development. Curr. Protoc. mouse Biol., 2016, 6:67-130

[42] Dempster DW et al. Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR histomorphometry nomenclature committee. J. Bone Miner. Res., 2013, 28:2-17

[43] Khan A et al. JASPAR 2018: update of the open-access database of transcription factor binding profiles and its web framework. Nucleic Acids Res., 2018, 46:D260-D266

Funding

U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)(AR067330)